The US Preventive Services Task Force has recently recommended the use of statins in primary prevention of cardiovascular disease in adults. Doubts remain as to whether this approach is really cost-effective, and additional drawbacks include the increasing burden of potential side effects and incremental costs due to laboratory monitoring.